This document summarizes the presentation of Dr. Sadia Sadiq on locally advanced breast cancer and chemotherapy. The presentation covers staging of breast cancer, local surgical treatments, management of the axilla, adjuvant and neoadjuvant chemotherapy. It discusses the evolution of surgical treatments from radical mastectomy to breast-conserving surgery plus radiation. It also summarizes landmark trials comparing different chemotherapy regimens and the addition of taxanes to anthracycline-based regimens. Finally, it notes that sequential therapy with anthracyclines/alkylators followed by taxanes was proven superior to concurrent taxane-anthracycline-alkylator treatments.
This document discusses locally advanced breast cancer and summarizes key points about its presentation, diagnosis, and treatment approaches. Approximately 20-25% of breast cancer patients present with locally advanced disease, including inflammatory breast cancer which represents 1-3% of cases. Long-term survival of around 50% is possible with a multimodality treatment approach. Neoadjuvant chemotherapy is effective for locally advanced, inoperable breast cancer and can improve surgical options. Anthracycline-based regimens like FEC and AC are common choices. The addition of taxanes may increase response rates. Neoadjuvant trastuzumab combined with chemotherapy significantly improves outcomes for HER2-positive locally advanced breast cancer.
Axillary radiotherapy provides comparable regional control to axillary lymph node dissection for breast cancer patients with positive sentinel nodes, with fewer side effects. The AMAROS trial found similar 5-year axillary recurrence, disease-free survival, and overall survival between the radiotherapy and dissection groups. However, radiotherapy resulted in significantly less lymphedema. While control was excellent with both treatments, the trial was underpowered to definitively show non-inferiority due to lower-than-expected axillary recurrences.
This document summarizes key landmark clinical trials in breast cancer. It discusses trials related to prevention using tamoxifen and raloxifene, radiation therapy trials for DCIS and early stage breast cancer, breast-conserving therapy including accelerated whole-breast irradiation, neoadjuvant chemotherapy trials, and HER2 targeted neoadjuvant therapy trials. The trials demonstrated the effectiveness of tamoxifen and radiation therapy in breast cancer prevention and treatment, and showed that hypofractionated radiation regimens and partial breast irradiation are not inferior to standard radiation protocols. Neoadjuvant chemotherapy was found to increase breast-conserving surgery rates and pathologic complete response rates. Dual HER2 blockade neoadjuvant regim
1) The PORTEC-1 and PORTEC-2 trials compared pelvic radiotherapy to no additional treatment or vaginal brachytherapy for patients with endometrial carcinoma. PORTEC-1 found pelvic radiotherapy reduced vaginal recurrence while PORTEC-2 found vaginal brachytherapy achieved excellent vaginal control with fewer side effects compared to pelvic radiotherapy.
2) The PORTEC-3 trial randomized 686 patients with high risk endometrial cancer to chemoradiotherapy or radiotherapy alone. It found chemoradiotherapy improved failure-free survival compared to radiotherapy alone, especially for stage III patients, but with increased toxicity.
3)
This document discusses the management of early breast cancer. It covers breast management including breast-conserving surgery and mastectomy. It discusses axillary management including axillary lymph node dissection and sentinel lymph node biopsy. It also discusses the roles of pre-operative systemic therapy, adjuvant therapy including anti-HER2 therapy, chemotherapy, and hormonal therapy based on breast cancer subtypes. The document provides guidelines on treatment options based on breast cancer stage and molecular profiles.
- Reirradiation or retreatments after initial radiotherapy is possible for 10% of cancer patients who experience a second cancer. However, if the radiation tolerance of a normal organ or tissue was exceeded in the initial treatment, reirradiation cannot be done safely.
- Early-responding tissues like skin generally recover better than late-responding tissues like fibrosis and can tolerate reirradiation with reduced doses. Spinal cord and lung data from rodent and monkey studies show some reirradiation is possible. Kidney and bladder do not recover from late damage.
- Clinical studies on reirradiation are limited but show it can provide local control and possibly survival for head and neck cancers, though with high risks of toxicity and functional
Role and Side effects of Ovarian Function Suppression in Breast CancerAjeet Gandhi
1) The document discusses the role and side effects of ovarian suppression therapy in premenopausal women receiving adjuvant treatment for hormone receptor positive breast cancer.
2) Key trials like SOFT and TEXT showed that the addition of ovarian suppression to tamoxifen or aromatase inhibitors improved disease-free survival rates and reduced the risk of breast cancer recurrence in premenopausal women compared to tamoxifen alone.
3) The benefits of ovarian suppression were greater in women who remained premenopausal after chemotherapy and those with larger/node-positive tumors or higher grade disease. Common side effects included hot flashes and musculoskeletal symptoms.
This document discusses locally advanced breast cancer and summarizes key points about its presentation, diagnosis, and treatment approaches. Approximately 20-25% of breast cancer patients present with locally advanced disease, including inflammatory breast cancer which represents 1-3% of cases. Long-term survival of around 50% is possible with a multimodality treatment approach. Neoadjuvant chemotherapy is effective for locally advanced, inoperable breast cancer and can improve surgical options. Anthracycline-based regimens like FEC and AC are common choices. The addition of taxanes may increase response rates. Neoadjuvant trastuzumab combined with chemotherapy significantly improves outcomes for HER2-positive locally advanced breast cancer.
Axillary radiotherapy provides comparable regional control to axillary lymph node dissection for breast cancer patients with positive sentinel nodes, with fewer side effects. The AMAROS trial found similar 5-year axillary recurrence, disease-free survival, and overall survival between the radiotherapy and dissection groups. However, radiotherapy resulted in significantly less lymphedema. While control was excellent with both treatments, the trial was underpowered to definitively show non-inferiority due to lower-than-expected axillary recurrences.
This document summarizes key landmark clinical trials in breast cancer. It discusses trials related to prevention using tamoxifen and raloxifene, radiation therapy trials for DCIS and early stage breast cancer, breast-conserving therapy including accelerated whole-breast irradiation, neoadjuvant chemotherapy trials, and HER2 targeted neoadjuvant therapy trials. The trials demonstrated the effectiveness of tamoxifen and radiation therapy in breast cancer prevention and treatment, and showed that hypofractionated radiation regimens and partial breast irradiation are not inferior to standard radiation protocols. Neoadjuvant chemotherapy was found to increase breast-conserving surgery rates and pathologic complete response rates. Dual HER2 blockade neoadjuvant regim
1) The PORTEC-1 and PORTEC-2 trials compared pelvic radiotherapy to no additional treatment or vaginal brachytherapy for patients with endometrial carcinoma. PORTEC-1 found pelvic radiotherapy reduced vaginal recurrence while PORTEC-2 found vaginal brachytherapy achieved excellent vaginal control with fewer side effects compared to pelvic radiotherapy.
2) The PORTEC-3 trial randomized 686 patients with high risk endometrial cancer to chemoradiotherapy or radiotherapy alone. It found chemoradiotherapy improved failure-free survival compared to radiotherapy alone, especially for stage III patients, but with increased toxicity.
3)
This document discusses the management of early breast cancer. It covers breast management including breast-conserving surgery and mastectomy. It discusses axillary management including axillary lymph node dissection and sentinel lymph node biopsy. It also discusses the roles of pre-operative systemic therapy, adjuvant therapy including anti-HER2 therapy, chemotherapy, and hormonal therapy based on breast cancer subtypes. The document provides guidelines on treatment options based on breast cancer stage and molecular profiles.
- Reirradiation or retreatments after initial radiotherapy is possible for 10% of cancer patients who experience a second cancer. However, if the radiation tolerance of a normal organ or tissue was exceeded in the initial treatment, reirradiation cannot be done safely.
- Early-responding tissues like skin generally recover better than late-responding tissues like fibrosis and can tolerate reirradiation with reduced doses. Spinal cord and lung data from rodent and monkey studies show some reirradiation is possible. Kidney and bladder do not recover from late damage.
- Clinical studies on reirradiation are limited but show it can provide local control and possibly survival for head and neck cancers, though with high risks of toxicity and functional
Role and Side effects of Ovarian Function Suppression in Breast CancerAjeet Gandhi
1) The document discusses the role and side effects of ovarian suppression therapy in premenopausal women receiving adjuvant treatment for hormone receptor positive breast cancer.
2) Key trials like SOFT and TEXT showed that the addition of ovarian suppression to tamoxifen or aromatase inhibitors improved disease-free survival rates and reduced the risk of breast cancer recurrence in premenopausal women compared to tamoxifen alone.
3) The benefits of ovarian suppression were greater in women who remained premenopausal after chemotherapy and those with larger/node-positive tumors or higher grade disease. Common side effects included hot flashes and musculoskeletal symptoms.
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinomaDr.Bhavin Vadodariya
This randomized controlled trial compared neoadjuvant chemoradiotherapy followed by surgery to upfront surgery followed by adjuvant therapy for patients with borderline resectable pancreatic cancer. It found that the neoadjuvant treatment approach significantly improved 2-year survival rates compared to upfront surgery. Specifically, the 2-year survival rate was 40.7% for the neoadjuvant group versus 26.1% for the upfront surgery group. The neoadjuvant approach also resulted in a higher R0 resection rate and median overall survival of 21 months compared to 12 months for upfront surgery. However, both approaches had similar recurrence rates, with most recurrences being systemic.
Landmark trials in breast Cancer surgery - NSABP 04,06,MILAN,EORTC 10853, ECO...Dr.Bhavin Vadodariya
1) The document summarizes key landmark trials in breast cancer surgery including the Halsted theory, Fisher theory, and results from NSABP B04, B06, and B17 trials which established breast conservation as a standard of care for early stage breast cancer.
2) It also discusses a trial evaluating cryoablation as a non-surgical option for small breast cancers and results showing 92% successful ablation with no residual disease after surgical resection.
3) Going forward, the document envisions more individualized and targeted breast cancer treatment based on genomic profiling of each tumor to identify markers and select the most appropriate targeted therapies or ablative procedures.
1) Short-course preoperative radiotherapy is an effective treatment for patients with operable rectal cancer, reducing the relative risk of local recurrence by 61% compared to selective postoperative chemoradiotherapy.
2) The addition of postoperative chemotherapy to preoperative chemoradiotherapy does not affect disease-free survival or overall survival in patients with stage T3 or T4 resectable rectal cancer.
3) Short-course preoperative radiotherapy followed by delayed surgery results in lower tumor stage, greater tumor regression grade, and higher pathologic complete response rates compared to long-course radiotherapy followed by delayed surgery, with potential improvements in overall survival and time to recurrence.
Peritoneal Carcinomatosis : Dr Amit DangiDr Amit Dangi
Here are the key steps:
1. The left subphrenic space is entered by incising the peritoneum overlying the left hemidiaphragm.
2. The peritoneum is dissected off the left hemidiaphragm in a cephalad direction towards the diaphragmatic crus.
3. The peritoneum is then stripped down the left paracolic gutter towards the pelvis, removing all peritoneal surfaces.
4. The left subphrenic peritonectomy is then completed, exposing the left hemidiaphragm and removing all peritoneal surfaces in the left subphrenic space.
The document discusses the role of chemotherapy in carcinoma of the stomach. It outlines several key trials investigating neoadjuvant, adjuvant and perioperative chemotherapy approaches. The MAGIC trial showed significantly improved 5-year survival with perioperative chemotherapy compared to surgery alone. The French FNCLCC trial also demonstrated improved disease-free and overall survival with perioperative chemotherapy. Adjuvant chemoradiation was shown in the INT0116/SWOG 9008 trial to improve 5-year overall and disease-free survival compared to surgery alone. The Japanese S-1 trial found significant benefit in 5-year disease-free and overall survival with adjuvant S-1 chemotherapy compared to observation after surgery.
approach for rectal carcinoma and managementrajendra meena
This document discusses the multidisciplinary approach to managing rectal carcinoma. It defines rectal carcinoma and provides details on incidence, risk factors, staging, diagnostic workup including various imaging modalities, and the roles of different specialists involved. It describes the prognostic factors and presents the tumor, node, metastasis (TNM) staging system. Surgical approaches like transanal local excision and total mesorectal excision are outlined. The roles of neoadjuvant therapy and advantages of pre-operative radiation are summarized. Clinical trials comparing outcomes of pre-operative versus post-operative chemoradiation are also reviewed.
1) Adjuvant chemoradiation improves local control for locally advanced rectal cancer compared to surgery alone based on multiple trials from the 1980s and 1990s.
2) Recent European trials have found no clear benefit of adjuvant chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer, with the exception of the QUASAR trial.
3) Adjuvant chemotherapy may be recommended after preoperative chemoradiation for mid-low rectal cancers with lymph node involvement (ypT3N+) or high rectal cancers with stage ypT2-3 based on trial results and expert guidelines.
This document summarizes several landmark clinical trials in breast cancer treatment. It describes trials that tested chemoprevention drugs like tamoxifen to reduce breast cancer risk. It also summarizes radiation therapy trials comparing lumpectomy alone to lumpectomy with radiation. Further, it summarizes trials comparing breast-conserving surgery and radiation to mastectomy. The document finds that radiation after lumpectomy and mastectomy radiation for node-positive patients improve outcomes.
Accelerated partial breast irradiation (APBI) delivers radiation to only the area around the tumor bed after breast-conserving surgery rather than the entire breast. Several techniques for APBI exist including interstitial brachytherapy, intracavitary brachytherapy, intraoperative radiation therapy, and external beam radiotherapy. Studies show local recurrence rates and cosmetic outcomes with APBI are comparable to whole breast irradiation, though longer follow up is still needed before APBI can be considered the new standard of care for early-stage breast cancer patients.
1) Locally advanced breast cancer is stage III breast cancer where the cancer has spread to nearby tissues but not distant sites. It is more common in developing countries due to lack of education and screening.
2) Investigations for locally advanced breast cancer include mammography, ultrasound, MRI of the breast and chest, CT scan of the abdomen and pelvis, bone scan, and PET scan to determine the extent of disease.
3) Treatment involves chemotherapy (usually followed by surgery if the tumor shrinks enough) or surgery followed by chemotherapy and radiation therapy. The type of surgery depends on the response to chemotherapy and may include breast-conserving surgery or mastectomy. Post-mastectomy radiation is usually recommended in several
Bladder preservation for CA Urinary BladderAnil Gupta
This document summarizes the case of a 74-year-old male patient with urinary bladder cancer who underwent bladder preservation treatment. He initially presented with hematuria and imaging found two bladder lesions, one of which was muscle-invasive. He received neoadjuvant chemotherapy followed by radical radiotherapy to the bladder, achieving a good response. Over 2.5 years of follow-up, he has remained with no evidence of disease and an intact, functional bladder. The document then discusses bladder cancer treatment approaches and evidence for bladder preservation with chemoradiotherapy as an alternative to radical cystectomy for select patients.
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
This document discusses total neoadjuvant therapy (TNT) for rectal cancer. It summarizes evidence from trials showing that TNT with chemotherapy prior to chemoradiation and surgery improves pathologic complete response rates and reduces distant metastases compared to adjuvant chemotherapy. The document also reviews the experience with TNT at the author's institution, including a clinical complete response rate of 36% and a pathologic complete response rate of 15.6% among surgery patients. Non-operative management strategies with a watch-and-wait approach are also discussed.
Omission of RT in elderly breast cancer patientsBharti Devnani
This journal club presentation summarized the PRIME II randomized controlled trial which evaluated the efficacy of postoperative whole-breast radiotherapy for women aged 65 years or older with early-stage, hormone receptor-positive breast cancer treated with breast-conserving surgery and adjuvant endocrine therapy. The results showed that radiotherapy achieved a significant but relatively small reduction in local breast recurrence at 5 years compared to no radiotherapy. However, the 5-year rate of recurrence was low enough that omission of radiotherapy could be considered for select low-risk patients based on tumor characteristics and patient preferences. Treatment decisions require individualization based on prognostic factors and risk-benefit assessment.
This document discusses the management of locally advanced breast cancer (LABC). Key points:
1. LABC includes stages IIIA, IIIB, IIIC breast cancer with large tumors (>5cm), chest wall involvement, skin ulcers, or fixed lymph nodes. Inflammatory breast cancer is an aggressive subtype of LABC.
2. Diagnosis involves history, physical exam, imaging like mammography and MRI, and biopsy. Staging workup includes labs, imaging of chest, abdomen, pelvis and bone.
3. Treatment involves neoadjuvant chemotherapy to downstage the cancer and allow for surgery. Surgery may include mastectomy or breast conservation. Postoperative radiation and endocrine therapy
Neoadjuvant therapy, including chemotherapy and chemoradiotherapy, is being investigated for the treatment of esophageal cancer. While some studies have shown improved survival rates with neoadjuvant therapy compared to surgery alone, the evidence from clinical trials remains conflicting. Achieving a complete pathological response after neoadjuvant therapy is associated with significantly improved long-term survival. Further research is still needed to determine the optimal neoadjuvant approaches and to improve outcomes by reducing distant metastases.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
Hypofractionation in Prostate Cancer: Is Less Enough?
1) The document discusses several studies that have compared hypofractionated radiation therapy (delivering larger doses of radiation in fewer treatments) to standard fractionation for prostate cancer. The PROFIT trial found equivalent 5-year outcomes for intermediate risk prostate cancer patients treated with either 60Gy in 20 fractions over 4 weeks or 78Gy in 39 fractions over 7-8 weeks, with less late gastrointestinal toxicity in the hypofractionated group.
2) The CHHiP trial also found non-inferior 5-year outcomes when comparing 60Gy in 20 fractions to 74Gy in 37 fractions for intermediate risk prostate cancer, with no difference in toxicity.
This document provides an overview of early breast carcinoma and ductal carcinoma in situ (DCIS). It discusses the management of lobular carcinoma in situ (LCIS) and DCIS, including surgical and radiation treatment options. It also covers the surgical management and adjuvant therapies for invasive breast cancer, such as the use of lumpectomy, lymph node dissection and radiation to lymph nodes. Emerging techniques for accelerated partial breast irradiation are also mentioned.
The document summarizes key landmark breast cancer trials that helped establish modern standards of care. The NSABP B-04 trial showed that modified radical mastectomy was as effective as radical mastectomy. The NSABP B-06 and Milan trials established breast-conserving surgery plus radiation as an equivalent alternative to mastectomy. The NSABP B-32 trial demonstrated sentinel node biopsy alone had similar outcomes as axillary dissection for node-negative cancer. Subsequent trials like ALMANAC and Z011 found sentinel node biopsy reduced arm morbidity without compromising survival. These trials provided critical evidence supporting less invasive surgical approaches for breast cancer.
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinomaDr.Bhavin Vadodariya
This randomized controlled trial compared neoadjuvant chemoradiotherapy followed by surgery to upfront surgery followed by adjuvant therapy for patients with borderline resectable pancreatic cancer. It found that the neoadjuvant treatment approach significantly improved 2-year survival rates compared to upfront surgery. Specifically, the 2-year survival rate was 40.7% for the neoadjuvant group versus 26.1% for the upfront surgery group. The neoadjuvant approach also resulted in a higher R0 resection rate and median overall survival of 21 months compared to 12 months for upfront surgery. However, both approaches had similar recurrence rates, with most recurrences being systemic.
Landmark trials in breast Cancer surgery - NSABP 04,06,MILAN,EORTC 10853, ECO...Dr.Bhavin Vadodariya
1) The document summarizes key landmark trials in breast cancer surgery including the Halsted theory, Fisher theory, and results from NSABP B04, B06, and B17 trials which established breast conservation as a standard of care for early stage breast cancer.
2) It also discusses a trial evaluating cryoablation as a non-surgical option for small breast cancers and results showing 92% successful ablation with no residual disease after surgical resection.
3) Going forward, the document envisions more individualized and targeted breast cancer treatment based on genomic profiling of each tumor to identify markers and select the most appropriate targeted therapies or ablative procedures.
1) Short-course preoperative radiotherapy is an effective treatment for patients with operable rectal cancer, reducing the relative risk of local recurrence by 61% compared to selective postoperative chemoradiotherapy.
2) The addition of postoperative chemotherapy to preoperative chemoradiotherapy does not affect disease-free survival or overall survival in patients with stage T3 or T4 resectable rectal cancer.
3) Short-course preoperative radiotherapy followed by delayed surgery results in lower tumor stage, greater tumor regression grade, and higher pathologic complete response rates compared to long-course radiotherapy followed by delayed surgery, with potential improvements in overall survival and time to recurrence.
Peritoneal Carcinomatosis : Dr Amit DangiDr Amit Dangi
Here are the key steps:
1. The left subphrenic space is entered by incising the peritoneum overlying the left hemidiaphragm.
2. The peritoneum is dissected off the left hemidiaphragm in a cephalad direction towards the diaphragmatic crus.
3. The peritoneum is then stripped down the left paracolic gutter towards the pelvis, removing all peritoneal surfaces.
4. The left subphrenic peritonectomy is then completed, exposing the left hemidiaphragm and removing all peritoneal surfaces in the left subphrenic space.
The document discusses the role of chemotherapy in carcinoma of the stomach. It outlines several key trials investigating neoadjuvant, adjuvant and perioperative chemotherapy approaches. The MAGIC trial showed significantly improved 5-year survival with perioperative chemotherapy compared to surgery alone. The French FNCLCC trial also demonstrated improved disease-free and overall survival with perioperative chemotherapy. Adjuvant chemoradiation was shown in the INT0116/SWOG 9008 trial to improve 5-year overall and disease-free survival compared to surgery alone. The Japanese S-1 trial found significant benefit in 5-year disease-free and overall survival with adjuvant S-1 chemotherapy compared to observation after surgery.
approach for rectal carcinoma and managementrajendra meena
This document discusses the multidisciplinary approach to managing rectal carcinoma. It defines rectal carcinoma and provides details on incidence, risk factors, staging, diagnostic workup including various imaging modalities, and the roles of different specialists involved. It describes the prognostic factors and presents the tumor, node, metastasis (TNM) staging system. Surgical approaches like transanal local excision and total mesorectal excision are outlined. The roles of neoadjuvant therapy and advantages of pre-operative radiation are summarized. Clinical trials comparing outcomes of pre-operative versus post-operative chemoradiation are also reviewed.
1) Adjuvant chemoradiation improves local control for locally advanced rectal cancer compared to surgery alone based on multiple trials from the 1980s and 1990s.
2) Recent European trials have found no clear benefit of adjuvant chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer, with the exception of the QUASAR trial.
3) Adjuvant chemotherapy may be recommended after preoperative chemoradiation for mid-low rectal cancers with lymph node involvement (ypT3N+) or high rectal cancers with stage ypT2-3 based on trial results and expert guidelines.
This document summarizes several landmark clinical trials in breast cancer treatment. It describes trials that tested chemoprevention drugs like tamoxifen to reduce breast cancer risk. It also summarizes radiation therapy trials comparing lumpectomy alone to lumpectomy with radiation. Further, it summarizes trials comparing breast-conserving surgery and radiation to mastectomy. The document finds that radiation after lumpectomy and mastectomy radiation for node-positive patients improve outcomes.
Accelerated partial breast irradiation (APBI) delivers radiation to only the area around the tumor bed after breast-conserving surgery rather than the entire breast. Several techniques for APBI exist including interstitial brachytherapy, intracavitary brachytherapy, intraoperative radiation therapy, and external beam radiotherapy. Studies show local recurrence rates and cosmetic outcomes with APBI are comparable to whole breast irradiation, though longer follow up is still needed before APBI can be considered the new standard of care for early-stage breast cancer patients.
1) Locally advanced breast cancer is stage III breast cancer where the cancer has spread to nearby tissues but not distant sites. It is more common in developing countries due to lack of education and screening.
2) Investigations for locally advanced breast cancer include mammography, ultrasound, MRI of the breast and chest, CT scan of the abdomen and pelvis, bone scan, and PET scan to determine the extent of disease.
3) Treatment involves chemotherapy (usually followed by surgery if the tumor shrinks enough) or surgery followed by chemotherapy and radiation therapy. The type of surgery depends on the response to chemotherapy and may include breast-conserving surgery or mastectomy. Post-mastectomy radiation is usually recommended in several
Bladder preservation for CA Urinary BladderAnil Gupta
This document summarizes the case of a 74-year-old male patient with urinary bladder cancer who underwent bladder preservation treatment. He initially presented with hematuria and imaging found two bladder lesions, one of which was muscle-invasive. He received neoadjuvant chemotherapy followed by radical radiotherapy to the bladder, achieving a good response. Over 2.5 years of follow-up, he has remained with no evidence of disease and an intact, functional bladder. The document then discusses bladder cancer treatment approaches and evidence for bladder preservation with chemoradiotherapy as an alternative to radical cystectomy for select patients.
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
This document discusses total neoadjuvant therapy (TNT) for rectal cancer. It summarizes evidence from trials showing that TNT with chemotherapy prior to chemoradiation and surgery improves pathologic complete response rates and reduces distant metastases compared to adjuvant chemotherapy. The document also reviews the experience with TNT at the author's institution, including a clinical complete response rate of 36% and a pathologic complete response rate of 15.6% among surgery patients. Non-operative management strategies with a watch-and-wait approach are also discussed.
Omission of RT in elderly breast cancer patientsBharti Devnani
This journal club presentation summarized the PRIME II randomized controlled trial which evaluated the efficacy of postoperative whole-breast radiotherapy for women aged 65 years or older with early-stage, hormone receptor-positive breast cancer treated with breast-conserving surgery and adjuvant endocrine therapy. The results showed that radiotherapy achieved a significant but relatively small reduction in local breast recurrence at 5 years compared to no radiotherapy. However, the 5-year rate of recurrence was low enough that omission of radiotherapy could be considered for select low-risk patients based on tumor characteristics and patient preferences. Treatment decisions require individualization based on prognostic factors and risk-benefit assessment.
This document discusses the management of locally advanced breast cancer (LABC). Key points:
1. LABC includes stages IIIA, IIIB, IIIC breast cancer with large tumors (>5cm), chest wall involvement, skin ulcers, or fixed lymph nodes. Inflammatory breast cancer is an aggressive subtype of LABC.
2. Diagnosis involves history, physical exam, imaging like mammography and MRI, and biopsy. Staging workup includes labs, imaging of chest, abdomen, pelvis and bone.
3. Treatment involves neoadjuvant chemotherapy to downstage the cancer and allow for surgery. Surgery may include mastectomy or breast conservation. Postoperative radiation and endocrine therapy
Neoadjuvant therapy, including chemotherapy and chemoradiotherapy, is being investigated for the treatment of esophageal cancer. While some studies have shown improved survival rates with neoadjuvant therapy compared to surgery alone, the evidence from clinical trials remains conflicting. Achieving a complete pathological response after neoadjuvant therapy is associated with significantly improved long-term survival. Further research is still needed to determine the optimal neoadjuvant approaches and to improve outcomes by reducing distant metastases.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
Hypofractionation in Prostate Cancer: Is Less Enough?
1) The document discusses several studies that have compared hypofractionated radiation therapy (delivering larger doses of radiation in fewer treatments) to standard fractionation for prostate cancer. The PROFIT trial found equivalent 5-year outcomes for intermediate risk prostate cancer patients treated with either 60Gy in 20 fractions over 4 weeks or 78Gy in 39 fractions over 7-8 weeks, with less late gastrointestinal toxicity in the hypofractionated group.
2) The CHHiP trial also found non-inferior 5-year outcomes when comparing 60Gy in 20 fractions to 74Gy in 37 fractions for intermediate risk prostate cancer, with no difference in toxicity.
This document provides an overview of early breast carcinoma and ductal carcinoma in situ (DCIS). It discusses the management of lobular carcinoma in situ (LCIS) and DCIS, including surgical and radiation treatment options. It also covers the surgical management and adjuvant therapies for invasive breast cancer, such as the use of lumpectomy, lymph node dissection and radiation to lymph nodes. Emerging techniques for accelerated partial breast irradiation are also mentioned.
The document summarizes key landmark breast cancer trials that helped establish modern standards of care. The NSABP B-04 trial showed that modified radical mastectomy was as effective as radical mastectomy. The NSABP B-06 and Milan trials established breast-conserving surgery plus radiation as an equivalent alternative to mastectomy. The NSABP B-32 trial demonstrated sentinel node biopsy alone had similar outcomes as axillary dissection for node-negative cancer. Subsequent trials like ALMANAC and Z011 found sentinel node biopsy reduced arm morbidity without compromising survival. These trials provided critical evidence supporting less invasive surgical approaches for breast cancer.
1) A landmark randomized clinical trial published in 1999 found that concurrent weekly cisplatin chemotherapy during pelvic radiation improved progression-free survival and overall survival rates for patients with bulky stage IB cervical cancer compared to radiation alone. The study demonstrated a 79% 5-year progression-free survival rate and 85% 5-year overall survival rate for patients receiving concurrent chemoradiation versus 74% and 63% respectively for radiation alone.
2) Another 1999 randomized clinical trial found that for high-risk cervical cancer patients, pelvic radiation with concurrent cisplatin and fluorouracil chemotherapy resulted in improved overall survival compared to pelvic and para-aortic radiation alone, establishing concurrent chemoradiation as the new standard
The document discusses breast-conserving treatment for early-stage breast cancer. Breast-conserving treatment, including wide local excision of the tumor, axillary lymph node dissection, and breast irradiation, is now the standard of care for most women with early-stage invasive breast cancer. Ideal candidates for breast-conserving treatment have unicentric primary tumors less than 4-5 cm in diameter. Contraindications include positive margins, advanced or multicentric disease, pregnancy, and prior radiation. The addition of a radiation boost to the tumor bed after whole breast irradiation reduces the risk of local recurrence. Hypofractionated regimens have been shown to be as effective as conventional fractionation with shorter treatment times.
This document summarizes several oral presentations made at the 36th Annual Conference of the Association of Radiation Oncologists of India. It includes summaries of studies on locally advanced breast cancer, locally advanced cervical cancer, laryngeal cancer, head and neck cancer, and cancer of the lip. One study found that adding paclitaxel to standard neoadjuvant chemotherapy improved outcomes for locally advanced breast cancer. Another study found that low-dose radiation prior to chemoradiation reduced tumor size and improved outcomes for cervical cancer. A third study compared outcomes and toxicities of different radiation techniques for laryngeal cancer.
1) Treatment guidelines increasingly tailor surgical, radiation, and medical approaches based on initial response to neoadjuvant systemic treatment.
2) Pathology and genomic assays refine prognosis and inform recommendations by classifying cancers as more favorable Luminal A vs B.
3) For early-stage HER2-positive breast cancer, pertuzumab added to trastuzumab-based adjuvant chemotherapy improves invasive disease-free survival compared to placebo.
Management of the axilla after neoadjuvant chemotherapyDr. Haytham Fayed
This document discusses surgical management of the axilla after neoadjuvant chemotherapy for breast cancer. It provides background on how axillary lymph node dissection was previously the standard approach but is now being reevaluated. Sentinel lymph node biopsy after neoadjuvant chemotherapy may accurately stage the axilla and spare some patients from axillary lymph node dissection if the sentinel nodes are negative, though identification rates are slightly lower than without chemotherapy. The document concludes that current evidence suggests an algorithm involving axillary ultrasound before and sentinel lymph node biopsy after neoadjuvant chemotherapy to guide need for further axillary lymph node dissection.
Marc Bollet : Role of radiation oncologist in neoadjuvant breast cancer trea...breastcancerupdatecongress
This document discusses the role of radiation oncologists in neoadjuvant treatment for breast cancer. It explores how radiotherapy could be part of neoadjuvant treatment when combined with hormone therapy or chemotherapy based on studies showing improved outcomes. The document also examines a phase II trial combining chemotherapy, radiotherapy and surgery that achieved a 27% pathological complete response rate and good long-term outcomes with acceptable toxicity levels. Finally, it discusses factors that could help predict tumor response and late toxicity from radiotherapy in the neoadjuvant setting.
This document discusses the evidence for adjuvant radiotherapy in breast cancer treatment. It finds that radiotherapy after breast-conserving surgery or mastectomy significantly reduces the risk of local recurrence and improves overall survival. For patients undergoing breast-conserving surgery, radiotherapy reduces the 10-year cumulative incidence of recurrence in the ipsilateral breast from 39.2% to 14.3%. Post-mastectomy radiotherapy is recommended for patients with ≥4 positive lymph nodes or 1-3 positive lymph nodes with high-risk features, as it lowers the risk of locoregional recurrence and improves overall survival. The timing, techniques, target volumes, and indications for radiotherapy are also outlined based on clinical evidence and guidelines.
Should triple negative breast cancer (tnbc) subtypeEreny Samwel
Triple-negative breast cancer (TNBC) is an aggressive subtype without targets for hormonal or HER2-directed therapy. While historically considered poor candidates for breast-conserving surgery, several studies have shown comparable or better outcomes for selected TNBC patients treated with lumpectomy and radiation compared to mastectomy. Genetic testing is recommended for TNBC patients to guide risk-reducing interventions, though mutation status alone should not determine local-regional management. Definitive local therapy combined with conventional radiation remains the standard of care for TNBC. Ongoing research aims to identify new targets for this challenging breast cancer subtype.
Should triple negative breast cancer (tnbc) subtypeErenyPoles
Triple-negative breast cancer (TNBC) is an aggressive subtype without targets for hormonal or HER2-directed therapy. While some studies found higher local recurrence rates with breast conservation for TNBC, other large studies found equivalent survival compared to mastectomy. Genetic testing is recommended for TNBC patients to guide risk-reducing interventions. For a patient with early-stage TNBC treated with lumpectomy, conventional whole-breast radiotherapy with boost is recommended to reduce the risk of local recurrence due to the aggressive nature of TNBC.
NEOADJUVANT THERAPY IN PANCREATIC CANCER.pptxSujan Shrestha
1) Several studies provide evidence supporting the use of neoadjuvant therapy for resectable pancreatic cancer. The PREOPANC-1 trial found no survival benefit for neoadjuvant chemoradiotherapy compared to upfront surgery in resectable pancreatic cancer. However, the Prep-02/JSAP-05 and PACT-15 trials found significantly improved survival with neoadjuvant chemotherapy compared to upfront surgery.
2) Guidelines such as ESMO and NCCN provide classifications for resectability and recommend considering neoadjuvant therapy for resectable pancreatic cancer with certain high-risk features or comorbidities.
3) Potential advantages of neoadjuvant therapy include managing micro
This document summarizes recent updates in the perioperative and surgical management of gastric cancer based on pivotal clinical trials. It discusses advances in minimally invasive surgery for early and locally advanced gastric cancer. It also reviews neoadjuvant treatment strategies against resectable locally advanced gastric cancer, highlighting several large phase 3 trials comparing neoadjuvant chemotherapy to upfront surgery. The document concludes with a discussion of postoperative adjuvant chemotherapy and trends emerging from landmark phase 3 trials.
Hypofractionated Radiotherapy in Breast Cancer.pptxAsha Arjunan
1) The document outlines studies evaluating hypofractionated whole breast radiotherapy (HF-WBI) for breast cancer treatment. The Ontario Clinical Oncology Group trial found local recurrence rates and overall survival were similar between HF-WBI (42.5 Gy in 16 fractions) and standard WBI (50 Gy in 25 fractions), with lower late toxic effects for HF-WBI.
2) The UK START trials also found similar local recurrence rates between HF-WBI schedules (39-41.6 Gy) and standard WBI (50 Gy), with lower normal tissue effects for HF-WBI. The UK FAST trial found mild/marked breast changes were higher for 30 Gy compared to 50 Gy but not for
Primary Surgery vs Chemoradiotherapy for Oropahryngeal CancerGloria Ate
This document summarizes a study comparing primary surgery versus chemoradiotherapy for advanced oropharyngeal cancers. The study analyzed data from 344 patients treated between 1998-2009 in Alberta, Canada. It found that patients receiving primary surgery followed by chemotherapy and radiotherapy (S-CRT) had significantly better survival rates than those receiving chemoradiotherapy (CRT) or surgery followed by radiotherapy (S-RT), with 5-year disease-specific survival rates of 71.1%, 48.6%, and 53.9% respectively. However, the role of HPV status on outcomes requires further investigation. The study generates questions about determining the optimal treatment approach for advanced oropharyngeal cancer.
The document summarizes evidence and guidelines for managing locally advanced rectal cancer. It discusses that neoadjuvant chemoradiation is preferred over postoperative chemoradiation based on trials showing lower local recurrence rates and less toxicity. Long-course neoadjuvant chemoradiation followed by surgery 6-8 weeks later is the standard approach. Post-treatment assessment of tumor response helps predict outcomes, with complete response indicating a good prognosis. Adjuvant chemotherapy after surgery may further improve survival based on meta-analyses of trials. Guidelines recommend a multidisciplinary, tailored approach incorporating staging, treatment response, and patient factors.
Clinical aspects of uh breast radiotherapySunilMaurya82
Clinical aspects of Ultra Hypofractionation in Ca Breast During CoVID 19 Pandamic By Dr Amol Kakade , Radiation oncologist , Sir HN RELIANCE HOSPITAL and Research center, Mumbai
A 71-year-old female presented with abdominal pain and weight loss. Imaging showed a mass in the pancreatic body involving nearby vessels. This represents locally advanced, unresectable pancreatic cancer. Treatment options include chemotherapy, radiation therapy, or chemoradiation to help control symptoms and prolong survival, though the prognosis remains poor. Surgery may be considered if the tumor significantly shrinks with neoadjuvant therapy.
a brief overview about management of ca breast.pptxSadia Sadiq
This document discusses the management of breast cancer from an oncologist's perspective. It covers topics such as staging, histopathology, treatment including chemotherapy, hormonal therapy, targeted therapy and radiation therapy. Key points discussed include the benefits of neoadjuvant chemotherapy, when radiation therapy is necessary, and clinical trials showing radiation therapy can sometimes be omitted in early breast cancer patients receiving hormonal treatment.
Recurrent Ca Endometrium Vaginal Interstitial.pptxSadia Sadiq
a case of recurrent endometrial cancer with vaginal involvement where free hand needle placement resulted in adequate target coverage and excellent response.
SFRT, also known as GRID therapy, treats tumors with a non-uniform radiation dose to effectively treat the tumor while staying within normal tissue tolerance. It has shown dramatic relief of symptoms, significant tumor regression, and minimal toxicity. Originally introduced in 1909 using perforated screens, modern techniques use MLCs or helical tomotherapy to create GRID-like dosimetry with improved flexibility and dosimetry. Studies show SFRT can achieve high response rates for various tumor types and has potential as a definitive treatment when combined with other therapies. Further clinical trials are warranted to evaluate its safety and efficacy for different cancer indications.
The document discusses the management of the axilla in breast cancer from a radiation oncologist's perspective. It covers how to stage the axilla through physical exam, imaging, or biopsy. For clinically node-negative patients, sentinel lymph node biopsy is standard, while clinically positive nodes may require lymph node dissection. Ongoing trials are exploring omitting further axillary treatment for some patients with positive nodes after neoadjuvant therapy. The conclusion emphasizes that axilla management remains controversial but aims for individualized treatment based on tumor characteristics and response to therapy.
Recent advances in the management of ovarian cancer include:
1) Optimal treatment of early-stage disease involves debulking surgery followed by carboplatin and paclitaxel chemotherapy based on trials showing improved recurrence-free and overall survival.
2) Maintenance therapy with bevacizumab or PARP inhibitors prolongs progression-free survival and overall survival compared to placebo in recurrent platinum-sensitive disease.
3) The role of secondary cytoreductive surgery and intraperitoneal chemotherapy in recurrent disease continues to be evaluated in ongoing clinical trials.
This document discusses the case of a 55-year-old woman diagnosed with Stage IA high-grade serous epithelial ovarian cancer. She underwent surgery followed by 6 cycles of carboplatin/paclitaxel adjuvant chemotherapy. She experienced recurrence 14 months later and underwent a second surgery and 6 cycles of gemcitabine/carboplatin chemotherapy. She had a second recurrence 4 months later and was started on topotecan and bevacizumab, showing a partial response. The document reviews trials on adjuvant chemotherapy for early-stage ovarian cancer and subsequent treatment options for platinum-resistant recurrence.
1) Breast cancer is the most common malignancy among females worldwide. Survival rates vary significantly based on cancer stage, with metastatic breast cancer having only a 26% 5-year survival rate.
2) Hormonal therapy is first-line treatment for hormone receptor-positive metastatic breast cancer. Tamoxifen and aromatase inhibitors are commonly used, with aromatase inhibitors showing improved outcomes compared to tamoxifen. Fulvestrant and newer targeted agents are options for progressed disease.
3) Chemotherapy is also used to treat metastatic breast cancer. Commonly used agents include taxanes like paclitaxel and docetaxel, anthracyclines like doxorubicin, and newer options
This document provides an overview of multiple myeloma, including its definition, clinical presentation, workup, staging, management, and treatment regimens. Key points include:
- Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in the bone marrow, leading to bone destruction.
- Workup involves blood and urine tests, bone marrow biopsy, skeletal survey, and imaging to determine disease severity and stage according to the Durie-Salmon or ISS staging systems.
- Treatment may include chemotherapy, steroids, immunomodulators, stem cell transplantation, and supportive care. The goal of initial therapy is to achieve remission prior to stem cell transplantation in eligible patients.
Stereotactic body radiation therapy (SBRT) is an evolution of stereotactic radiosurgery that delivers high-dose radiation to tumors in fewer fractions than conventional radiotherapy. It requires extra-ordinary care due to the precision needed to target tumors while sparing surrounding tissues from damage. SBRT has shown efficacy in treating various tumor types including lung, liver, spine, pancreas and prostate cancers with acceptable toxicity risks when proper quality assurance procedures and motion management techniques are followed.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Advanced breast cancer & chemo by me
1. DR SADIA SADIQ
PGR 4,INMOL
LOCALLYLOCALLY
ADVANCED CAADVANCED CA
BREAST &BREAST &
CHEMOTHERAPYCHEMOTHERAPY
2. PRESENTATION OUTLINEPRESENTATION OUTLINE
STAGING
LOCAL SURGICAL
TREATMENT
MANAGEMENT OF
AXILLA
ADJUVANT
CHEMOTHERAPY
NEO-ADJUVANT
CHEMO THERAPY
TOPICS NOT
COVERED
Genetics
Workup
Noninvasive Breast
Cancer
Metastatic Breast
Cancer
Hormonal Therapy
Targetted Therapy
Radiation Therapy
3.
4. LOCAL MANAGEMENT OFLOCAL MANAGEMENT OF
INVASIVE CANCERINVASIVE CANCER
Theevaluation of the patient newly
diagnosed with breast cancer begins
witha determination of operability.
In the patient with clinicalstage I, II, and
T3N1 disease, the initial management is
usually surgical
Patients with T4 tumors and those with N2 or
N3 nodal disease are not candidates for surgery as
the first therapeutic approach and should
be treated with systemic therapy initially
5. SURGICAL TREATMENTSURGICAL TREATMENT
HALSTEDIAN ERAHALSTEDIAN ERA
WILLIAM HALSTED(1894) popularised radical
mastectomy as the treatment of choice for breast
cancer ,considered breast cancer strictly as a
locoregional disease.
6. HALSTEDIAN PRINCIPLEHALSTEDIAN PRINCIPLE
Tumor spreads in an orderdly pattern
Lymphnodes acts as barrier to spread, blood stream
is of little significance
More radical the surgery , more the chance of cure
Recurrance & death are due to inadequacy of
surgery
7. FISHER CONCEPTFISHER CONCEPT
During the second half of 19th
century
alternate hypothesis (Fisher
Concept)emerged which stressed breast
cancer as a systemic disease.
Operable breast cancer is a systemic disease
Blood stream is of considerable importance
for tumour dissemination
No orderly spread
Regional lymph nodes are of biological
importance
8. NSABP B-04NSABP B-04
Between 1971-74, 1765 patients from 34 institutions
across USA and Canada participated.
Objective was to find whether reducing the extent of
surgery might not compromise outcome.
Two companion trials conducted in parallel –one for
those with clincally node negative patients and other
for clinically node positive patients.
Radical Mastectomy served as control arm for both.
9. SCHEMASCHEMA
No difference in overall survival
among 3 arms in clinically node
negative patient.25% for RM arm,
19% for TM/radiation arm, 26%
for TM.
P=0.38, Confidence Interval:0.91
to 1.28
In node positive patients overall
survival 14% in each arm.
P=0.72,Confidece Interval :0.87-
1.23
CONCLUSION :
MRM = RM
(OS,DFS)
11. MRM vs BCS+RTMRM vs BCS+RT
The NSABP B-06 trial, along with other trials
conducted by the Milan group to evaluate
quadrantectomy, was instrumental in the
establishment of breast conserving surgery plus
radiotherapy as the preferred method of local
treatment for patients with operable breast cancer.
OBJECTIVE : To find whether LUMPECTOMY &
AXILLARY DISSECTION with or without
RADIOTHERAPHY is better than TOTAL
MASTECTOMY with AXILLARY DISSECTION in
early stage breast cancer (stage I & IIwith tumour
size < 4 cm,N0/N1)
13. NSABP 6: BCS +RT BETTER THANNSABP 6: BCS +RT BETTER THAN
BCS ALONEBCS ALONE
After 25 years of follow-
up, the cumulative
incidence of a
recurrence of tumor in
the ipsilateral breast
was 39 percent in the
group treated with
lumpectomy alone and
14 percent in the group
treated with
lumpectomy and breast
irradiation (P<0.001)
14. RISK FACTORS FOR LOCALRISK FACTORS FOR LOCAL
RECURRENCR AFTER BCS+RTRECURRENCR AFTER BCS+RT
15. LOCAL RECURRENCE AFTERLOCAL RECURRENCE AFTER
BCS…INCREASED?BCS…INCREASED?
The incidence of LR after BCT has
Declined over time,from 10-year rates
of 8% to 19% seen in retrospective
studies and the initial Randomized
trials of BCT,to 2% to 7% in patients
excised to negative margins in more
recent studies.
17. Importance of Axillary Lymph NodeImportance of Axillary Lymph Node
StatusStatus
Nodal status determines stage, predicts outcome
Nodal status influences adjuvant therapy
decisions:
- Chemotherapy, anti-estrogen therapy
- Drug choice, dose, combination
- Radiation therapy
ALND provides excellent long term control with only
1.4% of pts in NSABP B-04 trial,treated with radical
mastectomy had isolated axillary recurrences at 10
year follow up.
18. SSlnb after neoadjuvantlnb after neoadjuvant
chemotherapychemotherapy
SLNB is a standard established procedure for
node negative early stage breast cancer. SLNB
after NAC is gradually being accepted for
operable node positive breast cancer patients
who turn out to be cN0 after NAC
NAC downstages axillary nodes in about 20-40% of
the patients
There is potential for decreasing the extent of
axillary surgery with SNB vs. AND if the axillary
nodes are down-staged with NAC
19.
20. RESULTS:
SLNB after NAC in biopsy proven node positive
patients results in reasonably acceptable FNR and
IR making it a valid alternative management
strategy to axillary dissection. More refined patient
selection and optimal techniques can improve the
FNR and INR in this patient population.
22. Evolution of ChemotherapyEvolution of Chemotherapy
Improvements in disease-free survival (DFS) with single-
agent chemotherapy after radical mastectomy in the 1970s.
Polychemotherapy was first evaluated by Bonadonna
– randomized women with node-positive breast cancer to 12
monthly cycles of cyclophosphamide, methotrexate, and 5-
fluorouracil (CMF) chemotherapy
– or no further therapy after radical mastectomy
23. Adjuvant ChemotherapyAdjuvant Chemotherapy
of Primary Breast Cancer:of Primary Breast Cancer:
Chemotherapy Improves Disease-Free and Overall
Survival
Polychemotherapy > Monochemotherapy
Multiple Cycles > Single Exposure
Anthracycline Combinations > CMF
Taxanes > anthracycline alone in node +ve and high
risk node –ve
Adriamycin Doses < 40mg/m2
are Inferior to 60 mg/m2
(CALGB 8541)
Cyclophosphamide Doses > 600 mg/m2
are not Superior (NSABP B-22)
Chemotherapy Seems More Effective in ER- Than ER+ Disease (EBCTCG)
24. RFS(HR 0.71) and OS(0.79)
in node +ve pts
RFS(HR 0.65) and
OS(HR 0.65) in node –
ve ER-ve pts
26. AT 5 years
RFS 63% vs 53%
OS 70% vs 77%
AT 10 years
RFS 52% vs 45%
OS 62% vs 58%
FEC vs CMF
27. BCIRG 001 TAC vs FACBCIRG 001 TAC vs FAC
After a median follow-up of 124 months, disease-free survival was
62% for patients in the TAC group and 55% for patients in the FAC
group (HR]0·80 ,long rank p=0·0043).
10-year overall survival was 76% for patients in the TAC group and
69% for patients in the FAC group (HR 0·74; log-rank p=0·0020)
1,480 women with node-positive
breast cancer
28. ADDITION OF PACLITAXEL TO ACADDITION OF PACLITAXEL TO AC
NSABP-B28 (Mamounas et al.
2005):
3,060 LN+ patients
randomized to
AC × 4 ± Paclitaxel.
Addition of taxane improved 5-
year DFS (72→76%) and LRR,
despite delay of RT (9.7 vs.
3.7%).
CALGB 9344 (Sartor et
al.2005;Henderson et al. 2003)
Randomization : Standard dose AC
vs. dose escalation of doxorubicin ±
sequential addition of paclitaxel.
At 5 years, the disease-free
survival rates were 65% for the
AC-treated cohort and 70% for
the AC-plus-paclitaxel treatment
group, and overall survival rates
were 77% and 80%, respectively.
No DFS or OS improvement
with dose escalation of
doxorubicin.
29. AC vs TCAC vs TC
USOT (Jones et al. 2009):
1,016 Stage I–III patients randomized to AC × 4 vs. TCx4.
With a median of 7-year follow-up,
TC improved DFS (81 vs. 75%) and OS (87% TC v
82).
TC improved outcomes regardless of age, hormone
receptor, or HER2 expression status.
31. When compared with the
standard every-3-week
paclitaxel arm, after a median
follow-up of 12.1 years, DFS
significantly improved and
overall survival (OS)
marginally improved only for
the weekly paclitaxel and
every-3-week docetaxel arms .
32. DOSE-DENSE TREATMENT ANDDOSE-DENSE TREATMENT AND
COCURRENT vs SEQUENTIALCOCURRENT vs SEQUENTIAL
Four-year disease-free survival was 82% for the dose-dense regimens and 75%
for the others. There was no difference in disease-free or overall survival
between the concurrent (dose-dense) and sequential schedules.
33. SequentialSequential therapytherapy withwith
anthracyclines/alkylatorsanthracyclines/alkylatorsfollowe by taxanes provedfollowe by taxanes proved
superiorsuperior toto concurrentconcurrent taxane-taxane-
anthracycline- alkylatoranthracycline- alkylator treatments.treatments.
BACKGROUND:
Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival
among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential
regimens is not known.
METHODS:
We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of
doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin
and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent
ACT). The primary aims were to examine whether concurrent ACT was more effective than sequential ACT and
whether the doxorubicin-docetaxel regimen would be as effective as the concurrent-ACT regimen. The secondary
aims were to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women.
RESULTS:
At a median follow-up of 73 months, overall survival was improved in the sequential-ACT group (8-
year overall survival, 83%) as compared with the doxorubicin-docetaxel group (overall survival, 79%; hazard ratio for
death, 0.83; P=0.03) and the concurrent-ACT group (overall survival, 79%; hazard ratio, 0.86; P=0.09). Disease-free
survival was improved in the sequential-ACT group (8-year disease-free survival, 74%) as compared with the
doxorubicin-docetaxel group (disease-free survival, 69%; hazard ratio for recurrence, a second malignant condition, or
death, 0.80; P=0.001) and the concurrent-ACT group (disease-free survival, 69%; hazard ratio, 0.83; P=0.01). The
doxorubicin-docetaxel regimen showed noninferiority to the concurrent-ACT regimen for overall survival (hazard ratio,
0.96; 95% confidence interval, 0.82 to 1.14). Overall survival was improved in patients with amenorrhea for 6 months
or more across all treatment groups, independently of estrogen-receptor status.
CONCLUSIONS:
Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it
improved overall survival as compared with doxorubicin-docetaxel. Amenorrhea was associated with improved survival
regardless of the treatment and estrogen-receptor status. (ClinicalTrials.gov number, NCT00003782.)
34. Typically, similar indications as adjuvant chemotherapy
Advantages of neoadjuvant chemotherapy:
–
assessment ofdisease response,
–
increased rate of BCT
–
Neoadjuvant chemotherapy converts 20–30% of patients
initially ineligible for BCT to eligible
–
Complete clinical (cCR) and pathological response rates
–
20–40% achieve cCR , 10–20% achieve pCR
–
Alow time for genetic testing
36. Clinical rationale for increasing useClinical rationale for increasing use
of neoadjuvant chemotherapyof neoadjuvant chemotherapy
Studies in experimental tumour models
Excellent clinical response rates in locally advanced breast cancer
(T3,T4 or TxN2)
Pathological CRs of up to 15%
Adjuvant chemotherapy has survival benefit in node positive and
negative breast cancer
Breast-conservation possible
37. NSABP B-18
N=1450
clinical T1-3, N0-1
ACACACAC
Surgery
Surgery
No difference in outcome chemotherapy preop vs postop:
DFS DDFS OS
ACACACAC
38. The outcomes of NACT was demonstrated in a 2007 meta-analysis
that included data from 5500 women participating in 1 of 14 trials
reported between 1991 and 2001. Compared to adjuvant
chemotherapy, NACT resulted in:
1. Equivalent overall survival (OS) (hazard ratio [HR] 0.98, 95% CI
0.87-1.09) and disease-free survival (DFS) (HR 0.97, 95% CI 0.89-
1.07)
2. Reduction in the risk of having a modified radical mastectomy
performed (HR 0.71, 95% CI 0.67-0.75)
3. An increased risk of locoregional recurrence (HR 1.21, 95% CI
1.02-1.43).
Meta-ANALYSISMeta-ANALYSIS
39. Those patients with a documented pathologic
complete response at surgery had significant
improvements in both OS (HR 0.48, 95% CI 0.33-
0.69) and DFS (HR 0.48, 95% CI 0.37-0.63)
compared to patients with residual invasive disease.
Pathological CRPathological CR
40. Meta analysis of Neoadjuvant Chemo Trials‐Meta analysis of Neoadjuvant Chemo Trials‐
12 randomized controlled trials for which pCR defined12 randomized controlled trials for which pCR defined
and DFS/OS data available (N=12993)and DFS/OS data available (N=12993)
41.
42. Can breast conservation be increasedCan breast conservation be increased
by PST ?by PST ?
Study Breast
Conservation
(%)
p
Scholl, 1994 82 vs 77 ns
Makris, 1998 89 vs 78 0.004
Fisher, 1998 67 vs 60 0.002
(RCTs of neoadjuvant vs adjuvant chemotherapy)
43. How should tumor location be documentedHow should tumor location be documented
Collaboration of surgical, medical oncologist and radiologist
Two major problems can occur:
– Either a very quick and complete response so that the primary
lesion cant be identified
– Or no response, in that case surgeon may have to intervene.
Precise documentation of the tumor on sketch, inserting clips
or coils in the center of the lesion or placing a tattoo
Stereo-tactic localization using mammography is another
option
Complete pathological CR becoming more common, so it
could become a major issue .
45. 4 cycles of Taxotere
4 cycles of CVAP
No Response
Response
Randomise
All Patients
4 cycles of
CVAP
First Phase
Smith et al, JCO 2002
Tax301 Study
Conducted by the Aberdeen Breast Group
Second phase
4 cycles of Taxotere
FinalAssessment/Surgery
47. NSABP B-27
Operable Breast CancerOperable Breast Cancer
RandomizationRandomization
AC x 4AC x 4
Tam X 5 YrsTam X 5 Yrs
AC x 4AC x 4
Tam X 5 YrsTam X 5 Yrs
AC x 4AC x 4
Tam X 5 YrsTam X 5 Yrs
SurgerySurgery Taxotere x 4Taxotere x 4 SurgerySurgery
SurgerySurgery Taxotere x 4Taxotere x 4
Bear et al, J Clin Oncol 2003; 21
( 2411 pts )
48.
49. GEPARDUO trialGEPARDUO trial
von Minckwitz et al., J Clin Oncol 1999
von Minckwitz et al., J Clin Oncol 2001
Surgery
Surgery
GeparduoGeparduo
TT ≥≥ 2 cm2 cm
(stage I,II)(stage I,II)
(N=913)(N=913)
AT + Tam
AC-T
+TAMAdriamycinAdriamycin
TaxotereTaxotere
AdriamycinAdriamycin
CyclophosphamideCyclophosphamide
TaxotereTaxotere
50.
51. Overview of Rand. Trial comparingOverview of Rand. Trial comparing
different Primary Systemic Therapydifferent Primary Systemic Therapy
Regimens in Breast CancerRegimens in Breast Cancer
54. ADJUVANT CHEMO:DEVITAADJUVANT CHEMO:DEVITA
Women who warrant chemotherapy,
Sequential anthracycline-and taxane-based treatment
remains the “gold standard.”
While multiple possible variations
on this regimen exist, the experience to
datehas not demonstrated that any regimen
is better tolerated or more effective
than AC for four cycles followed by paclitaxel
chemotherapy, with paclitaxel given as
either four cycles every 2 weeks, or
as 12 weeks of weekly therapy.
55. Meanwhile, neither additional
chemotherapy doses nor agents have
improved outcomes.
Multiple studies have failed to demonstrate
that dose escalation of cyclophosphamide or
doxorubicin results in a lower risk of
recurrence.
Theaddition of capecitabine or gemcitabine
to anthracycline-and taxane- based
chemotherapy regimens did not improve
efficacy.
56. Hormone receptor status may be an important
predictor of benefit from chemotherapy.
Tumors that are low or nonexpressors of ER
derive substantial benefit from the addition of
chemotherapy to tamoxifen;
By contrast, tumors with high quantitative levels of
ER do not appear to gain substantially from
adding chemotherapy to endocrine therapy.
HER2 overexpression is associated with a
relative benefit from anthracycline-based
chemotherapy,and HER2 tumors do not selectively
benefit from anthracyclines, as opposed to
CMF type chemotherapy treatments